Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Dummer

Showing results (251-260 of 328) with videos related to

Pageof 33
Sort By:
Dermatology (Basel, Switzerland)|January 1, 1995
Lymphomatoid papulosis--treatment with recombinant interferon alfa-2a and etretinateM Wyss, R Dummer, S N Dommann, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|December 8, 2016
Developments in targeted therapy in melanomaV C Amann, E Ramelyte, S Thurneysen, et al.
The British Journal of Dermatology|August 23, 2019
Binimetinib in heavily pretreated patients with NRAS-mutant melanoma with brain metastasesS M Goldinger, A Valeska Matter, U Urner-Bloch, et al.
British Journal of Cancer|May 29, 2008
The influence of sentinel lymph node tumour burden on additional lymph node involvement and disease-free survival in cutaneous melanoma--a retrospective analysis of 392 casesM Guggenheim, R Dummer, F J Jung, et al.
BMC Cancer|April 16, 2020
Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effectJ Boegeholz, C S Brueggen, C Pauli, et al.
Cancer|May 1, 1991
Formation of neutralizing antibodies against natural interferon-beta, but not against recombinant interferon-gamma during adjuvant therapy for high-risk malignant melanoma patientsR Dummer, W Müller, F Nestle, et al.
Cancer Gene Therapy|August 5, 2000
Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumorsR Dummer, J Bergh, Y Karlsson, et al.
The American Journal of Pathology|September 11, 2001
Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 productionM Urosevic, M O Kurrer, J Kamarashev, et al.
The British Journal of Dermatology|March 26, 2003
Pyogenic lymphoma of the skin: a peculiar variant of primary cutaneous neutrophil-rich CD30+ anaplastic large-cell lymphoma. Clinicopathological study of four cases and review of the literatureG Burg, W Kempf, D V Kazakov, et al.
The British Journal of Dermatology|August 29, 2012
Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056)S Whittaker, P Ortiz, R Dummer, et al.
Pageof 33

Showing results (251-260 of 328) with videos related to

Sort By:
Pageof 33
Dermatology (Basel, Switzerland)|January 1, 1995
Lymphomatoid papulosis--treatment with recombinant interferon alfa-2a and etretinateM Wyss, R Dummer, S N Dommann, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|December 8, 2016
Developments in targeted therapy in melanomaV C Amann, E Ramelyte, S Thurneysen, et al.
The British Journal of Dermatology|August 23, 2019
Binimetinib in heavily pretreated patients with NRAS-mutant melanoma with brain metastasesS M Goldinger, A Valeska Matter, U Urner-Bloch, et al.
British Journal of Cancer|May 29, 2008
The influence of sentinel lymph node tumour burden on additional lymph node involvement and disease-free survival in cutaneous melanoma--a retrospective analysis of 392 casesM Guggenheim, R Dummer, F J Jung, et al.
BMC Cancer|April 16, 2020
Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effectJ Boegeholz, C S Brueggen, C Pauli, et al.
Cancer|May 1, 1991
Formation of neutralizing antibodies against natural interferon-beta, but not against recombinant interferon-gamma during adjuvant therapy for high-risk malignant melanoma patientsR Dummer, W Müller, F Nestle, et al.
Cancer Gene Therapy|August 5, 2000
Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumorsR Dummer, J Bergh, Y Karlsson, et al.
The American Journal of Pathology|September 11, 2001
Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 productionM Urosevic, M O Kurrer, J Kamarashev, et al.
The British Journal of Dermatology|March 26, 2003
Pyogenic lymphoma of the skin: a peculiar variant of primary cutaneous neutrophil-rich CD30+ anaplastic large-cell lymphoma. Clinicopathological study of four cases and review of the literatureG Burg, W Kempf, D V Kazakov, et al.
The British Journal of Dermatology|August 29, 2012
Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056)S Whittaker, P Ortiz, R Dummer, et al.
Pageof 33